Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

2.910 +0.010 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Editas Medicine

< Previous 1 2 3 Next >
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 2/28
Via Investor Brand Network
Editas Medicine Inc. (NASDAQ: EDIT) Near the Top of Equities by Percentage Gain on 9/29
Via Investor Brand Network
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via GlobeNewswire
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.